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METFORMIN ASSOCIATED INFLAMMATION LEVELS REGULATION IN TYPE 
2 DIABETES MELLITUS-TUBERCULOSIS COINFECTION PATIENTS  – A CASE 
REPORT 
 
ABSTRACT 
1.    IFN-γ elevation is one of the indicators of successful treatment in active tuberculosis (TB)  
2. infection due to macrophage and Th-1 activation in inducing autophagy process. However,  
3. IL-10 also inhibits interferon-mediated mycobactericid activities by blocking IFN-γ  
4. signaling pathways in autophagy. Therefore, ratio IFN-γ / IL-10 has to be greater than 1  
5. (>1) then IFN-γ remains has anti-mycobacterium. Metformin (MET) is a potent  
6. combination drug to elevate anti-TB efficacy and able to regulate inflammation.  
7.    In this study, an observational clinical study was done in diabetes mellitus (DM)-TB co- 
8. infection outpatients at Surabaya Paru Hospital. This study evaluated how MET therapy  
9. affected inflammation. MET was used at least 2 months, accompanying with insulin and  
10. anti-TB and as comparison to non MET group.  
11.    The result in this study MET increased both pro-inflammatory and anti-inflammatory  
12. cytokines, thus MET may consider as adjunct therapy in DM-TB coinfection patients due  
13. to its ability in Th-1 and Th-2 immuno-regulating response, especially to enhance IFN-γ   
14. and to reduce insulin associated  IL-10 upregulation. 
 
Keywords: type 2 diabetes mellitus-tuberculosis co-infection; metformin; ratio interferon 
gamma and interleukin-10 
 
1. INTRODUCTION 
15.    Mycobacterium tuberculosis (M. tuberculosis) infection or known by TB infection is a  
16. leading cause of global morbidity and mortality thus, requiring long-term therapy1,2.  
17. There are five phases of M.tuberculosis infection and divided into two main phase. Firstly  
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18. is invasion phase (phase 1-2) and secondly is immunological phase, this phase is happened  
19. due to the immunology response during interaction of M. tuberculosis and host (phases 3- 
20. 5) 3. Invasion phase occurs when M. tuberculosis reaches the pulmonary alveoli and  
21. becomes colony in the lung with its ability to avoid the phagocytosis. In phase 2,  
22. M.tuberculosis multiplies in immature nonactivated macrophages to form a lesion called  
23. tubercle. In invasion phase, anti TB works well to eliminate M. tuberculosis. However, the  
24. efficacy of anti TB reduce in immunology phase, which the host body starts limit M.  
25. tuberculosis by developing caseous necrosis as immune response against tuberculin-like  
26. antigens released by M.tuberculosis in phase 3, then becomes liquefaction phase in phase  
27. 4 to 5 to limited tuberculosis extracellular multiplication 3,4. The aimed of anti-TB  
28. therapy is curing patients, preventing death, preventing recurrence, cutting off transmission  
29. chains and preventing germ resistance by eradication of M.tuberculosis. The effectiveness  
30. of rifampicin, isoniazid, pyrazinamide and ethambutol is influenced by host immune  
31. response5,6.Therefore, new approach is needed to enhance anti TB efficacy during  
32. immunology phase. One of offered suggestion was compiled MET during intensive phase  
33. of anti-TB therapy. 
34.  
35.     Metformin hydrochloride (MET), biguanide, use in type 2 diabetes mellitus by 1)  
36. inhibiting the production of hepatic glucose; 2) reducing intestinal glucose absorption; and  
37. 3) improving glucose uptake and utilization  5,7,8.  MET is known affecting inflammation  
38. mediators, both pro-inflammation, such IFN-γ, IL-β and also anti-inflammation such IL-10  
39. 8–10. Interferon (IFN)-γ is a potent cytokine that indicates antimicrobial effect and also  
40. modulates the production or activities of several cytokines and chemokines 11–13.  IFN- 
41. γ activates macrophages and dendritic cells to perform autophagy to M. Tuberculosis, and  
42. diminished of IFN-γ relates to anti-tuberculosis therapy failure14–18.  
43.  
3 
 
2. MATERIALS AND METHODS 
1.1 Study Design  
44.    In this study, an observational clinical study was done in diabetes mellitus (DM)-TB co-  
45. infection outpatients at Surabaya Paru Hospital. It involved two groups, MET group as  
46. observation group, and non MET group. The MET group was receiving MET therapy with  
47. doses from 1000 mg to 1500 mg along with insulin and anti-TB during the intensive  
48. periods. The enrolled patients criterias: 1) patient DM with a new case of TB co-infection,  
49. who were given insulin and anti-TB regimens; 2) positive sputum smear; 3) Patient’s age  
50. was 25 to 60 years old; 4) has normal liver function and renal function; 5) not in hypoxia  
51. condition, presenting by peripheral oxygen saturation level must be higher than  92%. 
52.  
53.     The levels of IFN-γ and IL-10 was measured before and after this observation period and  
54. as a clinical result, we also evaluated the smear reversion in DM-TB coinfection patients in  
55. both groups. 
2.2 Diagnosis and Management Therapy  
56.    The diagnosis of TB was established by 1) clinical symptoms and signs of TB, such:  
57. chronic productive cough, unintentional weight loss; 2) positive sputum smear of acid-fast  
58. bacilli (AFB) by microscopic Ziehl-Neelsen-stained sputum slides; and 3) chest  
59. radiographs with suggestive features of TB. The diagnosis of DM was established by  
60. fasting blood sugar > 120mg/dL; HbA1c > 7%.  
61.  
62.     Patients diagnosed with TB were registered and treated with anti-TB for 6 months in  
63. accordance to WHO guidelines19,20. Insulin use for achieving good glycaemic control  
64. in the patients in this study. These following drugs were used: MET (Metformin(R)), insulin  
65. (Humulin(R)), rifampicin (RIF), isoniazid (INH), pyrazinamide (PYR), ethambutol (ETH).  
66. MET were given 1000 – 1500 mg in the divided daily dose for at least two months or during  
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67. the intensive phase of anti-TB therapy. 
 
2.3 Acid Fast Bacilli Smears (AFB) Smears 
68.    Sputum smears were examined two times : 1) before treatment in order to diagnose and  
69. 2) after the intensive phase of anti-TB treatment in order to do evaluation. 
 
2.4 Cells Culture and ELISA 
70.    Cells and ELISA. Cells. PBMC was obtained from patients’ whole blood and 1x106  
71. were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 0,1μg  
72. mantoux and 0,7 μg penicilline. Supernatant were harvested after 72 hours and prepare for  
73. ELISA methods in order to measure the levels of IFN-γ and IL-10. ELISA. IFN-γ (RnD  
74. DIF50) and IL-10 (RnD P113058) were used as measurement kits. 
 
3. RESULT  
3.1 Characteristic of patients  
75.    This study’s ethical clearance was approved by ethical committee of Surabaya Paru  
76. Hospital with no. 09.01/KERS/102.6/2016 and written informed consent obtained from all  
77. participants after information for consent was given by the investigators. During this study  
78. period, there were 476 cases of new TB infection and 156 cases (~30%) of that were type  
79. 2 DM-TB co-infection. 42 patients were eligible participated in this observational studies.  
80. All the basic conditions in both groups were homogeneous (p > 0,05) (as seen in table 1). 
81.  
82.    In order to prevent MET associated lacto acidosis (MALA) during MET therapy in this  
83. study, all patients has been determined as mention at enrolled patients criterias (data was  
84. as seen in table 1). Moreover, there was no incidence of lactic acidosis event during this  
85. observation period21.  
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86.  
87.     During observation weeks (intensive phase of anti-TB therapy), we also obtained fasting  
88. blood sugar (FBS) levels periodically and the FBS levels were also similar in both groups  
89. (as seen in Figure 1). This data show that IFN-γ and IL-10 elevation in this study might be  
90. not directly influenced by hyperglycemia condition. 
91.  
92.     For sputum smears, as seen in Table 2 shows that prior to the intensive phase of anti-TB  
93. therapy none of the subjects were having negative AFB in both groups. The highest number  
94. of AFB count (+3) in MET group was 40.9% and in non MET group was 35%. After 2  
95. months MET therapy accompanying with insulin and anti-TB regimens, all patients in MET  
96. group were AFB reversion (negative smears result), while only 75% of non MET group  
97. had AFB reversion. Using the Fisher's exact test, results of different test p = 0.046  
98. (p<0.005), which means there is a significantly difference of AFB smears reversion  
99. between the MET group and the non MET group. 
 
3.2 IFN-γ, IL-10 and ratio IFN-γ, IL-10 
100. 3.2.1 IFN-γ. IFN-γ is activated by Th1 and NK Cells to induce macrophage and  
101. dendritic cell activation thus provide protection against TB infection22,23. Increased  
102. of IFN-γ in chronic TB infection is a cellular immune response. Currently, IFN-γ release  
103. assay (IGRA) is used as one of the tools of diagnosis of latent TB infection and IFN-γ  
104. elevation is one of the indicators of successful treatment in active TB infection24.  
105.  
106.     Using Wilcoxon-Mann Whitney, nonparametric statistical test, figure 2 shows that  
107. IFN-γ level before treatment between MET group and non MET group were alike  
108. (p>0,005), thus it shows that patients in both groups, before treatment, were in the  
109. similar stage of IFN-γ. The differences before and after observation period was  
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110. significant in MET group  (p<0,005) while in non MET group was not. Referring to  
111. negative AFB in MET group after 2 months intensive therapy (as seen in figure 2), it 
supports that IFN-γ has effect as mycobactericid. 
112.  
113. 3.2.2 IL-10. . IL-10 has ability to inhibit the Th-1pro-inflammation cytokines, including  
114. IFN-γ23–25. Using Wilcoxon-Mann Whitney, nonparametric statistical test, figure 3  
115. shows that IL-10 level before treatment between MET group and non MET group were  
116. alike (p>0,005), thus it shows that patients in both groups, before treatment, were in the  
117. similar stage of IL-10. Although IL-10 level was increased, the differences before and  
118. after observation period was not significant between MET and nongroup  (p>0,005). 
119.  
120. 3.2.3 Ratio IFN-γ / IL-10. Ratio IFN-γ / IL-10 shows that immune processes inside the  
121. host were more dominated by pro-inflammatory or anti-inflammatory cytokines after  
122. intensive phase of anti-TB with or without MET therapy. Whenever the IFN-γ / IL-10  
123. ratio is greater than 1 (>1), thus the host’s immunity defense system was dominated by  
124. pro-inflammation condition26. 
125.  
126.      Using Wilcoxon-Mann Whitney, table 3 shows that ratio IFN-γ / IL-10 were not  
127. significant difference before and after the intensive phase of anti-TB therapy between  
128. MET and non MET group  (p>0,005). However, IFN-γ / IL-10 ratio difference variation  
129. after MET combined anti-TB and insulin was narrower than non MET group. 
 
4. DISCUSSION  
130.    IFN-γ is the chief cytokine involved in the protective immune response against  
131. mycobacterial infection11,27,28. The main function of  IFN-γ is macrophage and  
132. dendritic cells activation, thus in this study autophagy marker was also high21 and it  
7 
 
133. referred to its mycobactericid functions. Predominantly IFN-γ is also contributed to less  
134. severe forms of pulmonary TB23. Moreover, IFN-γ also enhances the antigen pre 
135. sentation through the induction of the expression of molecules from the major  
136. histocompatibility complex (MHC) class I and class II and promoting the differentiation  
137. of CD4 T lymphocytes to the Th1 subpopulation 11,22. Furthermore as conclusion in  
138. this study MET associated to inflammation regulatory in DM-TB coinfection patients.  
139. However, IFN-γ relates to CD8 T-lymphocytes or cytotoxic T-cells also contributes to  
140. lung tissue damaged, thus  IFN-γ activity needs to be controlled22,23.  
141.  
142.     IL-10 a major anti-inflammatory cytokines plays important role in metabolic disorder  
143. such diabetes due its affect to insulin sensitivity29. IL-10 is produced by macrophages  
144. and Th-2 during M. tuberculosis infection It suppresses macrophage function and  
145. inhibits pro-inflammation cytokines such IFN-γ, TNF-σ and IL-1β. The increase in IL- 
146. 10 levels appears to support the mycobacterial survival in the host23 due to the  
147. inhibition of autophagy targeting signals through IL-10 activated SOCS3, and then,  
148. SOCS3 inhibits the Janus kinase-2 (Jak2)/signal transducer and activator of transcription  
149. (Stat) pathway in activating macrophage autophagy27,28. In this study, the increasing  
150. of IL-10 may happen not only due to macrophage related Th-2 activation but also due  
151. to insulin attenuated anti-inflammation regulatory29–32.  
152.  
153.      Based on this result, MET therapy may consider as new  strategy in enhancing anti  
154. TB efficacy due to its two main ability : 1) MET controlled IL-10 secretion thus alter  
155. host immune response against TB infection; and; 2) MET also affects to insulin  
156. sensitivity thus enhanced insulin therapy.  
157.  
158.     Regulating pro-inflammatory and anti-inflammatory cytokines is a critical role in the  
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159. immunity and progression of inflammation. Knowing the use of “old” drug, MET, for  
160. new  strategy in conquering TB was the purpose of this case-study. As conclusion in this  
161. study, MET increased both pro-inflammatory and anti-inflammatory cytokines, thus  
162. MET may consider as adjunct therapy in type 2 DM-TB coinfection patients due to its  
163. ability in Th-1 and Th-2 immuno-regulating response. However, the further study  
164. requires in knowing MET attenuated host sensitivity against M. tuberculosis infection  
165. in a larger number of DM-TB coinfection patients. 
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